Searching. Please wait…
1582
37
171
29406
4423
2606
347
392
Abstract: This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
Fuente: Lancet Oncol . 2021 Mar;22(3):e105-e118
Publisher: Lancet Pub. Group
Year of publication: 2021
No. of pages: 14
Publication type: Article
DOI: 10.1016/S1470-2045(20)30756-7
ISSN: 1470-2045,1474-5488
Publication Url: https://www.doi.org/10.1016/S1470-2045(20)30756-7
Google Scholar
Citations
Read publication
MOREAU, PHILIPPE
KUMAR, SHAJI K
SAN MIGUEL, JESÚS
DAVIES, FAITH
ZAMAGNI, ELENA
BAHLIS, NIZAR
LUDWIG, HEINZ
MIKHAEL, JOSEPH
TERPOS, EVANGELOS
SCHJESVOLD, FREDRIK
MARTIN, THOMAS
YONG, KWEE
DURIE, BRIAN G M
FACON, THIERRY
JURCZYSZYN, ARTUR
SIDANA, SURBHI
RAJE, NOOPUR
DONK, NIELS VAN DE
LONIAL, SAGAR
ENRIQUE MARIA OCIO SAN MIGUEL
Back